Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from MedX Health ( (TSE:MDX) ).
MedX Health Corp. has launched a non-brokered private placement of up to $5 million in Series IV convertible loan notes, bearing 6% annual interest and maturing on December 31, 2028, with an investor option to convert into equity units priced at $0.10 per unit, each consisting of one common share and half a warrant exercisable at $0.125. The financing, which requires a minimum subscription of $2.65 million and is subject to regulatory and stock exchange approvals, will be used to redeem outstanding Series I notes where not exchanged, support ongoing development and commercial rollout of MedX’s SIAscopy on DermSecure telemedicine platform, expand into the occupational health market, and fund general corporate purposes, potentially strengthening its balance sheet and advancing its market position in digital dermatology.
More about MedX Health
MedX Health Corp., based in Ontario, Canada, is a data-enabled medical technology company specializing in non-invasive skin screening and teledermatology via its proprietary SIAscopy imaging technology and DermSecure cloud-based platform. The company targets early detection of skin cancer and broader digital dermatology and skin care services for clinical, research, and beauty and aesthetics markets, with regulatory clearances in Canada, the U.S., Australia, New Zealand, the U.K., the EU and Turkey.
Average Trading Volume: 87,003
Technical Sentiment Signal: Sell
Current Market Cap: C$19.62M
See more insights into MDX stock on TipRanks’ Stock Analysis page.